Who Should Receive AOD 9604 Peptide Therapy
In the FY 2026 IPPS/Long Term Care Hospital (LTCH) proposed rule (90 FR 18266), consistent with current law, based on IHS Global, Inc.'s (IGI's) fourth quarter 2024 forecast, the proposed FY 2026 IPPS market basket percentage increase was 3.2 percent
The Absence of Robust Human Clinical Evidence Despite widespread interest, there is a stark reality: there are no large-scale, randomized controlled human trials evaluating BPC-157 for musculoskeletal or systemic healing
In models of quadriceps muscle crush injury, BPC-157 preserved muscle function and dramatically accelerated regeneration
However, lower systemic exposure from oral delivery is not automatically "safer," since under-dosed compounds may still carry unknown long-term risks without providing benefit
Animal studies and small human trials have shown peptides can: Support tissue repair and wound healing